Corresponding Author:
Steven G. DuBois, MD
Pediatric Oncology
Dana-Farber Cancer Institute
450 Brookline Avenue, Dana 3
Boston, MA 02215
Telephone: 617-632-5460
Facsimile: 617-632-4811
Email: steven_dubois@dfci.harvard.edu
Running Head: Cabozantinib plus topotecan/cyclophosphamide
Discipline: Pediatric Oncology
Key Words: cabozantinib, topotecan, cyclophosphamide, relapsed osteosarcoma, relapsed Ewing sarcoma, phase 1
Grant Support: Supported by T32 training grant 5T32CA136432-10 (KC), Alex’s Lemonade Stand Center of Excellence (KC, DSS, NC, WBL, SGD), Conquer Cancer Foundation (KC), and the Jimmy Fund Hyannisport Classic (SGD).
Disclosures: SGD reports travel expenses from Loxo Oncology, Roche, and Salarius and consulting fees from Amgen, Bayer, and Jazz. WBL reports consulting fees from Merck Sharp & Dohme Corp, Jubilant Draximage Inc, and Y-mAbs Therapeutics, Inc.
Manuscript Word Count: 2,782